LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Hospital Ramón y Cajal
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Ramón y Cajal (36)
2024
-
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases
Lung Cancer, Vol. 188
-
RET Fusion Testing in Patients With NSCLC: The RETING Study
JTO Clinical and Research Reports, Vol. 5, Núm. 4
-
The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium
Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362
2023
-
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
The Lancet Respiratory Medicine, Vol. 11, Núm. 1, pp. 74-86
-
Correction to: New update to the guidelines on testing predictive biomarkers in non‑small‑cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2022), 10.1007/s12094-022-03046-9)
Clinical and Translational Oncology
-
New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia, Vol. 56, Núm. 2, pp. 97-112
-
New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 25, Núm. 5, pp. 1252-1267
2022
-
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
Nature Medicine, Vol. 28, Núm. 8, pp. 1640-1645
2021
-
Impact of the COVID-19 pandemic on the care of cancer patients in Spain
ESMO open, Vol. 6, Núm. 3, pp. 100157
-
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888
-
Overview of virus and cancer relationships. Position paper
Revista Espanola de Quimioterapia, Vol. 34, Núm. 6, pp. 525-555
-
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer
Clinical Cancer Research, Vol. 27, Núm. 4, pp. 992-1003
-
Tumor mutational burden assessment in non-small-cell lung cancer samples: Results from the TMB 2 harmonization project comparing three NGS panels
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 5
2020
-
Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts
Radiotherapy and Oncology, Vol. 149, pp. 84-88
-
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 759-771
2019
-
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132
-
Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts
Radiotherapy and Oncology, Vol. 133, pp. 163-166
2018
-
Aligning digital CD8
+
scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma
Histopathology, Vol. 72, Núm. 2, pp. 270-284
-
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer
European Respiratory Journal
2017
-
A consensus statement on the gender perspective in lung cancer
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 527-535